These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 19514618)

  • 21. Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction.
    Heusch G; Kleinbongard P
    Drugs; 2016 May; 76(7):733-40. PubMed ID: 27041289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limited role for ivabradine in the treatment of chronic heart failure.
    Cullington D; Goode KM; Cleland JG; Clark AL
    Heart; 2011 Dec; 97(23):1961-6. PubMed ID: 21917660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Heart rate reduction due to selective specific inhibition of the If current opens new possibilities in treatment of basic cardiovascular diseases].
    Chichkanov GG; Tsorin IB
    Eksp Klin Farmakol; 2013; 76(2):37-42. PubMed ID: 23631283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heart rate reduction in heart failure: ivabradine or beta blockers?
    Guglin M
    Heart Fail Rev; 2013 Jul; 18(4):517-28. PubMed ID: 22972475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The discovery of the selective I(f) current inhibitor ivabradine. A new therapeutic approach to ischemic heart disease.
    Vilaine JP
    Pharmacol Res; 2006 May; 53(5):424-34. PubMed ID: 16638639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L
    Eur J Heart Fail; 2010 Jan; 12(1):75-81. PubMed ID: 19892778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.
    Kosmala W; Holland DJ; Rojek A; Wright L; Przewlocka-Kosmala M; Marwick TH
    J Am Coll Cardiol; 2013 Oct; 62(15):1330-8. PubMed ID: 23916925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The discovery of the selective If current inhibitor ivabradine (Procoralan): a new therapeutic approach to ischemic heart disease].
    Vilaine JP
    Med Sci (Paris); 2006 Jan; 22(1):87-94. PubMed ID: 16386229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.
    Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
    Lancet; 2008 Sep; 372(9641):817-21. PubMed ID: 18757091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.
    DiFrancesco D; Camm JA
    Drugs; 2004; 64(16):1757-65. PubMed ID: 15301560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease.
    Dillinger JG; Maher V; Vitale C; Henry P; Logeart D; Manzo Silberman S; Allée G; Levy BI
    Hypertension; 2015 Dec; 66(6):1138-44. PubMed ID: 26418022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ivabradine on left ventricular remodelling after reperfused myocardial infarction: A pilot study.
    Gerbaud E; Montaudon M; Chasseriaud W; Gilbert S; Cochet H; Pucheu Y; Horovitz A; Bonnet J; Douard H; Coste P
    Arch Cardiovasc Dis; 2014 Jan; 107(1):33-41. PubMed ID: 24440004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R; Ceconi C
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):959-73. PubMed ID: 21878041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New pharmacological approaches to ischemic heart disease].
    Raddino R; Della Pina P; Gorga E; Brambilla G; Regazzoni V; Gavazzoni M; Dei Cas L
    G Ital Cardiol (Rome); 2012 Oct; 13(10 Suppl 2):50S-54S. PubMed ID: 23096376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
    Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
    Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ivabradine: A Current Overview.
    Guha K; Allen CJ; Hartley A; Sharma R
    Curr Clin Pharmacol; 2016; 11(4):241-249. PubMed ID: 27784216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A New Insight on Anti-Ischemic Action of Ivabradine in Patients With Stable Angina].
    Kobalava ZD; Shavarov AA; Kiyakbaev GK
    Kardiologiia; 2017 Mar; 57(3):68-74. PubMed ID: 28762939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
    Borer JS; Böhm M; Ford I; Robertson M; Komajda M; Tavazzi L; Swedberg K;
    Am J Cardiol; 2014 Feb; 113(3):497-503. PubMed ID: 24332674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction.
    Foster JL; Bobadilla RV
    J Am Assoc Nurse Pract; 2016 Nov; 28(11):576-582. PubMed ID: 27215699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Heart rate: a risk factor or an epiphenomenon?].
    Metra M; Zacà V; Lombardi C; Bugatti S; Dei Cas L
    G Ital Cardiol (Rome); 2010 Mar; 11(3):209-20. PubMed ID: 20550061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.